5-氨基-2-乙氧基吡啶 | 52025-34-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氨基-2-乙氧基吡啶
• 中文别名: 5-氨基-2-乙氧基砒啶
• 英文名称: 5-amino-2-ethoxypyridine
• 英文别名: 6-ethoxypyridin-3-amine；2-ethoxy-5-aminopyridine
• CAS: 52025-34-0
• 化学式: C₇H₁₀N₂O
• mdl: MFCD01646194
• 分子量: 138.169
• InChiKey: UXIPFCIFZLFXNC-UHFFFAOYSA-N

物化性质

• 熔点：
  67.5-68.5 °C
• 沸点：
  269.5±20.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 海关编码：
  2933399090
• 安全说明：
  S36

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Amino-2-ethoxypyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-2-ethoxypyridine
CAS number: 52025-34-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O
Molecular weight: 138.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基-2-乙氧基吡啶 在 palladium on activated charcoal 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 21.0h， 生成 3-(6-Ethoxypyridin-3-yl)imidazo[4,5-b]pyridin-6-amine
  参考文献：
  名称：

  Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles

  摘要：

  A series of potent arenavirus inhibitors sharing a benzimidazole core were previously reported by our group. SAR studies were expanded beyond the previous analysis, which involved the attached phenyl rings and methylamino linker portion, to include modifications focused on the benzimidazole core. These changes included the introduction of various substituents to the bicyclic benzimidazole ring system along with alternate core heterocycles. Many of the analogs containing alternate nitrogen-based bicyclic ring systems were found to retain antiviral potency compared to the benzimidazole series from which we derived our lead compound, ST-193. In fact, 21h, built on an imidazopyridine core, possessed a near tenfold increase in potency against Lassa virus pseudotypes compared to ST-193. As found with the benzimidazole series, broad-spectrum arenavirus activity was also observed for a number of the analogs discovered during this study. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.093
• 作为产物：
  描述：

  2-乙氧基-5-硝基吡啶 在 钯 氢气 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to give 2.892 g of 2-ethoxy-5-aminopyridine as a gold solid的产率得到5-氨基-2-乙氧基吡啶
  参考文献：
  名称：

  Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands

  摘要：

  本发明涵盖了Formula1的结构或其药学上可接受的非毒性盐，其中：X为氢、卤素、(未)取代烷基、(未)取代烷氧基或氨基；Y为(未)取代烷基、芳基或杂环芳基，这些化合物是高度选择性的GABAa脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAa脑受体激动剂、拮抗剂或反向激动剂的前药。这些化合物在焦虑、唐氏综合症、睡眠、认知和癫痫障碍、苯二氮平类药物过量和警觉性增强的诊断和治疗中有用。

  公开号：

  US20020156280A1

文献信息

• [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013012500A1

  公开（公告）日：2013-01-24

  The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.

  本发明涉及式（I）中的螺环氨基甲酸酯化合物，其中R1，（R2）Y，R3，R4，X和A具有规范中给定的含义。该发明还提供含有这些化合物或其药用可接受盐的药物组合物，并涉及将这些化合物用作TRPV4拮抗剂以治疗或预防与TRPV4失衡相关的疾病。
• TANK-BINDING KINASE INHIBITOR COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160096827A1

  公开（公告）日：2016-04-07

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  具有以下化学式（I）的化合物以及它们的使用和制备方法已被披露：
• [EN] PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS<br/>[FR] INHIBITEURS ANTIGRIPPAUX À LARGE SPECTRE À BASE DE PYRIDAZINONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018001948A1

  公开（公告）日：2018-01-04

  The present invention relates to compounds of formula (I): (I) or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

  本发明涉及以下式(I)的化合物或其药用盐，以及其制备方法、包含它们的药物组合物，以及它们作为药物的用途。
• Tetraazabenzo[e]azulene derivatives and analogs thereof
  申请人：Elliott L. Richard

  公开号：US20050267100A1

  公开（公告）日：2005-12-01

  This invention relates to CCK-A agonists of Formula (I) wherein R 1 -R 4 , A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity.

  这项发明涉及公式（I）中的CCK-A激动剂， 其中R1-R4，A，B，X，D，E和G如规范中所定义，以及包含这些化合物的药物组合物和这些化合物和组合物的使用方法。这些化合物在治疗肥胖症方面是有用的。
• GPR119 Receptor Agonists
  申请人：Erickson Shawn David

  公开号：US20090286812A1

  公开（公告）日：2009-11-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  提供以下公式(I)的化合物： 以及可药用的接受盐，其中取代基如说明书中所披露。这些化合物以及含有它们的药物组合物可用于治疗代谢性疾病和障碍，例如，2型糖尿病。